| Literature DB >> 24391528 |
Wilfredo Hernández1, Juan Paz1, Fernando Carrasco2, Abraham Vaisberg3, Evgenia Spodine4, Jorge Manzur5, Lothar Hennig6, Joachim Sieler6, Steffen Blaurock6, Lothar Beyer6.
Abstract
The palladium(II) bis-chelate complexes of the type [Entities:
Year: 2013 PMID: 24391528 PMCID: PMC3874341 DOI: 10.1155/2013/524701
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Scheme 1Synthesis of 4-phenyl-1-acetone thiosemicarbazone, 4-phenyl-1-benzaldehyde thiosemicarbazone, and 4-phenyl-1-naphthaldehyde thiosemicarbazone ligands.
Scheme 2Synthesis of palladium(II) bis-chelate complexes of acetone, benzaldehyde, and naphthaldehyde thiosemicarbazone derivatives.
Crystal data and structure refinement for HTSC3, HTSC4, and [Pd(TSC1)2].
| Compound | HTSC3 | HTSC4 | [Pd(TSC1)2] |
|---|---|---|---|
| Empirical formula | C14H13N3OS | C18H15N3S | C20H24N6S2Pd |
| Formula weight | 271.33 | 305.39 | 518.97 |
| Temperature (K) | 213 | 213 | 213 |
| Crystal system | Triclinic | Orthorhombic | Monoclinic |
| Space group | P-1 | P212121 | C2/c |
|
| 6.3202(7) | 5.3471(3) | 23.456(2) |
|
| 10.357(1) | 15.7563(9) | 7.7080(4) |
|
| 11.506(1) | 16.456(2) | 12.3813(10) |
|
| 65.95(1) | 90 | 90 |
|
| 80.14(1) | 90 | 97.96(1) |
|
| 85.32(1) | 90 | 90 |
| Volume (Å3) | 677.56(13) | 1554.91(18) | 2216.9(3) |
|
| 2 | 4 | 4 |
| Density (g/cm3) | 1.33 | 1.305 | 1.555 |
| Absorption coeff. (mm−1) | 0.234 | 0.208 | 1.044 |
| Crystal size (mm) | 0.7 × 0.3 × 0.2 | 0.7 × 0.05 × 0.05 | 0.4 × 0.4 × 0.4 |
|
| 3–28 | 2–26 | 3–28 |
| Index ranges | −7 ≤ | − 6 ≤ | − 30 ≤ |
| −13 ≤ | − 18 ≤ | −9 ≤ | |
| −15 ≤ | − 22 ≤ | −16 ≤ | |
| Reflections collected | 7186 | 10232 | 10366 |
| Independent reflections | 2997 | 3005 | 2662 |
| Max./min. transmission | 0.8534/0.9547 | 0.8683/0.9897 | 0.7171/0.9674 |
| Data/parameters | 2997/224 | 3005/259 | 2662/180 |
| Goodness-of-fit on | 0.803 | 0.804 | 0.841 |
| Final |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
| Lgst diff. peak/hole ( | 0.19/−0.16 | −0.1/0.03 | −0.31/0.07 |
Bond length (Å) and torsion angles (°) for HTSC3 and HTSC4.
| HTSC3 | HTSC4 |
|---|---|
| C2-N2 1.280(2) | C8-N3 1.278(2) |
| N2-N1 1.382(2) | N3-N2 1.380(2) |
| N1-C1 1.352(2) | N2-C7 1.351(2) |
| C1-N3 1.347(2) | C7-N1 1.351(2) |
| C1-S1 1.689(1) | C7-S1 1.688(2) |
| N3-C9 1.430(2) | N1-C1 1.414(2) |
| C2-N2-N1-C1 173.8(1) | C8-N3-N2-C7 180.0(2) |
| N2-N1-C1-N3 5.33(2) | N3-N2-C7-N1 1.0(2) |
| N1-C1-N3-C9 −177.1(1) | N2-C7-N1-C1 −176.8(2) |
Selected bond lengths (Å) and angles in (°) for [Pd(TSC1)2] (6).
| Distances | Angles |
|---|---|
| Pd1-S1 2.270(1) | N1-Pd1-S1 82.21(4) |
| Pd1-N1 2.099(1) | Pd1-S1-C4 95.20(6) |
| N1-N2 1.421(2) | S1-C4 -N2 125.7(1) |
| N2-C4 1.290(2) | C4-N2-N1 112.6(2) |
| C4-S1 1.773(2) | N2-N1-Pd1 117.3(1) |
Figure 1Molecular structure of HTSC3 (3). The displacement ellipsoids are drawn at the 50% probability.
Figure 2Molecular structure of HTSC4 (4). The displacement ellipsoids are drawn at the 50% probability.
Figure 3Molecular structure of [Pd(TSC1)2] (6). The displacement ellipsoids are drawn at the 50% probability.
Figure 4Double chain structure of HTSC3 in the crystal.
Figure 5Helix structure of HTSC4 in the crystal.
IC50 (µm) valuesa of the ligands HTSC1–5, palladium(II) complexes [Pd(TSC1–5)2], and cisplatin against the different human tumor cell linesb.
| Human tumor cell lines | H460 | DU145 | MCF-7 | M14 | HT-29 | K562 |
|---|---|---|---|---|---|---|
| HTSC1 | >250 | >250 | >250 | >250 | >250 | 70.86 |
| HTSC2 | >250 | 31.55 | 38.05 | >250 | >250 | 32.89 |
| HTSC3 | 23.48 | 26.64 | 34.00 | 28.67 | 25.73 | 35.05 |
| HTSC4 | 39.65 | 26.45 | 29.94 | >250 | >250 | 24.66 |
| HTSC5 | 24.95 | 31.60 | 25.46 | 27.31 | 26.72 | 27.76 |
| [Pd(TSC1)2] | 9.40 | 8.27 | 6.95 | 9.87 | 8.20 | 9.43 |
| [Pd(TSC2)2] | 2.26 | 2.05 | 1.61 | 2.14 | 1.87 | 1.95 |
| [Pd(TSC3)2] | 0.23 | 0.01 | 0.13 | 0.05 | 0.05 | 0.02 |
| [Pd(TSC4)2] | 2.05 | 2.39 | 2.14 | 2.27 | 2.37 | 1.84 |
| [Pd(TSC5)2] | 0.68 | 0.84 | 0.78 | 1.06 | 1.04 | 0.65 |
| cisplatin | 2.85 | 6.50 | 7.20 | 2.95 | 7.60 | 3.20 |
aIC50 corresponds to the concentration required to inhibit 50% of the cell growth when the cells are exposed to the compounds during 48 h. Each value is the average of two independent experiments.
bLung large cell carcinoma (H460), prostate carcinoma (DU145), breast adenocarcinoma (MCF-7), amelanotic melanoma (M-14), colon adenocarcinoma (HT-29), and chronic myelogenous leukemia (K562).
Figure 6The antiproliferative activity in vitro expressed as IC50 (μM) values of the ligands HTSC1–5 and palladium(II) complexes [Pd(TSC1–5)2] against (a) H460 and (b) K562 human tumor cell lines after 48 h incubation time.
Figure 7The antiproliferative activity in vitro expressed as IC50 (μM) values of the ligands HTSC1–5, palladium(II) complexes [Pd(TSC1–5)2], and cisplatin against MCF-7 human tumor cell line after 48 h incubation time.